Bank of America
APLS

Bank of America’s Apellis Pharmaceuticals APLS Stock Holding History

Bank of America’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-84,100
Closed -$5.03M – 7712
2023
Q4 		$5.03M Buy
84,100
+31,400
+60% +$1.59M ﹤0.01% 3551
2023
Q3 		$2M Buy
+52,700
New +$2.31M ﹤0.01% 4238
2021
Q4 		– Sell
-149,200
Closed -$4.92M – 8188
2021
Q3 		$4.92M Buy
+149,200
New +$8.38M ﹤0.01% 3583

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of America's APLS Position: Q2 2026 in Review

Bank of America sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,190,864 shares — an estimated $47.9M sold.

Bank of America first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $68.5M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Bank of America reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bank of America sold 1,190,864 Apellis Pharmaceuticals shares in Q2 2026, an estimated $47.9M.
  • Bank of America first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
  • Bank of America's Apellis Pharmaceuticals position peaked at $68.5M in Q1 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.